EGFR and breast carcinoma: Our finding that PYK2 acts at the crossroads of ErbB- and IL8-receptor signaling pathways (Figure 8) to potentiate breast cancer invasion suggests that it could be an effective therapeutic target for invasive and/or metastatic breast carcinoma.